NCT04113564已完成1 期
A Randomized, Open-label, Single-dose, 2-way Crossover Study to Compare the Relative Bioavailability of Orally Administered Remimazolam to an Intravenous Formulation in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Absolute oral bioavailability of remimazolam
研究概览
简要总结
A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing to participate in the study, willing to give written informed consent prior to the initiation of any protocol-specific procedures, and willing to comply with the study restrictions.
- •Had to be able to speak, read, and understand English sufficiently to allow completion of all study assessments.
- •Gender : males and/or females
- •Age : 18 - 55 years, inclusive
- •Body mass index (BMI) : 18.0 - 32.0 kg/m2
- •Weight : ≥50 kg
- •Healthy status was defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, clinical chemistry, serology, and urinalysis.
- •Ability and willingness to abstain from alcohol, caffeine, and xanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical facility on Day -1 until study discharge.
- •All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator.
- •Females of childbearing potential and males and their female partner(s) of childbearing potential had to agree to use 2 forms of contraception, 1 of which had to be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception were condom and diaphragm. Acceptable non-barrier forms of contraception for this study were an intrauterine device (IUD) and/or spermicide.
- •For females: a negative pregnancy test at Screening and Day -
- •Postmenopausal females: defined as 12 months with no menses prior to Screening and a serum follicle stimulating hormone (FSH) >40 IU/L at Screening.
- •All non-regular medication (including over-the-counter [OTC] medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol (acetaminophen), which was allowed up to admission to the clinical research center.
排除标准
- •Women who were pregnant or lactating.
- •Males with female partners who were pregnant or lactating.
- •Use of any investigational drug or device within 30 days of the first dose of study medication.
- •Any disease which, in the opinion of the Investigator, posed an unacceptable risk to the subjects.
- •Known allergy, hypersensitivity or prior intolerance to benzodiazepine derivates or flumazenil, or a medical condition such that these agents were contraindicated.
- •The use of tobacco products within 60 days prior to the first drug administration.
- •Routine or chronic use of more than 3 grams of acetaminophen daily.
- •Strenuous activity, sunbathing and contact sports within 48 hours (2 days) prior to admission to the clinical facility and for the duration of the study.
- •History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research center or planned donation before 30 days had elapsed since intake of study drug.
- •Plasma or platelet donation within 7 days of dosing and throughout the entire study.
- •History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption was prohibited from 48 hours prior to admission to the clinical facility and throughout the entire study until discharge.
- •Positive screening test for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.
- •Positive results for drugs of abuse, including cotinine, in the urine at Screening or Day -
- •Positive results for alcohol abuse, as determined by alcohol breath test, at Screening or Day -
- •Inability to be venipunctured or tolerate venous access as determined by the Investigator or designee.
- •History of clinically significant, recent/current and nonremote suicidal ideations or suicide attempts that, in the opinion of the Investigator, posed an unacceptable risk to the subject for participating in the study.
- •Any major surgery within 4 weeks of study drug administration. NOTE: Any parameter/test could be repeated at the Investigator's discretion during Screening and/or on Day -1.
研究组 & 干预措施
IV remimazolam
Experimental
IV remimazolam administration of 0.025 mg/kg body weight
干预措施: Remimazolam (Drug)
Oral remimazolam
Experimental
Oral remimazolam Administration of 0.14 mg/kg Body weight
干预措施: Remimazolam (Drug)
结局指标
主要结局
Absolute oral bioavailability of remimazolam
时间窗: Day 1 (pre-dode) to Day 3
Single-dose bioavailability of an oral formulation of remimazolam relative to an IV formulation of remimazolam in healthy male and female subjects
次要结局
- Time to Maximum Plasma concentration (Tmax)(Day 1 (pre-dode) to Day 3)
- Maximum Plasma concentration (Cmax)(Day 1 (pre-dode) to Day 3)
- Elimination half-life (T1/2)(Day 1 (pre-dode) to Day 3)
- Volume of Distribution (Vz/F)(Day 1 (pre-dode) to Day 3)
- Clearance (CL/F)(Day 1 (pre-dode) to Day 3)
- Area under the plasma concentration-time curve (AUC0-t)(Day 1 (pre-dode) to Day 3)
- Incidences of Treatment-emergent adverse events(Day 1 (pre-dode) to Day 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male SubjectsSolid TumorNCT04351165Impact Therapeutics, Inc.18
已完成
1 期
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid TumoursBreast Cancer, Colorectal CancerNCT01493336Hoffmann-La Roche37
已完成
1 期
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed ConditionHealthyNCT01064115Dr. Reddy's Laboratories Limited30
已完成
1 期
Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of DolutegravirHIV InfectionsNCT03095638ViiV Healthcare38
已完成
1 期
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult ParticipantsHealthyNCT02117505Janssen Research & Development, LLC20